Pankaj R Shah & Associates
Chartered Accountants

CA. DR. Pankaj Shah B.Com., F.C.A., Ph. D. (Commerce) | CA. Chintan Shah B.Com., L.L.B., F.C.A. | CA. Nilesh Shah B.Com., L.L.B., F.C.A. | CA. Manali Shah B.Com., F.C.A. | CA. Sandip Gupta B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. **URL : http://www.prsca.in**

Independent Auditors Limited Review Report on the Quarter ended Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, (the "Listing Regulations").

Review Report to,
The Board of Directors
Senores Pharmaceuticals Limited,

We have reviewed the consolidated statement of unaudited consolidated financial results of **Senores Pharmaceuticals Limited** (the "company") for the quarter ended on 30th June, 2026 (the "statement") including its subsidiary's share of net profit/ after tax and total comprehensive income/loss, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

The statement includes the results of the following entities;
Parent:
Senores Pharmaceuticals Limited

Subsidiary:

1. Senores Pharmaceuticals INC
2. Ratnatris Pharmaceuticals Private Limited
3. Havix Group INC
4. Apnar Pharma Private Limited

Step down Subsidiary:

1. 9488 Jackson Trail LLC
2. Zoraya Pharmaceuticals LLC
3. Amerisyn LLC

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS ★ AHMEDABAD ★

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The accompanying statements includes unaudited interim financial results of 4 subsidiaries and 3 Stepdown subsidiaries included in the statement, whose unaudited interim financial results reflect total revenues Rs.181.19 Crores, total net profit after tax of Rs. 31.22 Crores and total comprehensive income is Rs. 31.22 crores for the quarter ended 30th June, 2026 respectively, as considered in the respective consolidated unaudited financial results. These unaudited interim financial results of this subsidiary has been reviewed by their auditors and have been approved and furnished to us by the management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such unaudited interim financial results and information. Our conclusion is not modified in respect of this matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date:27-07-2026
Place: Ahmedabad

For, Pankaj R Shah & Associates
Chartered Accountants
Registration No.107361W

N. R. Shah

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

CA Nilesh Shah
Partner
Membership No.107414
UDIN: 26107414PGXPKX5989

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | **Website:** www.senorespharma.com | **Phone:** +91-79-29999857 | **E-mail:** cs@senorespharma.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30,2026

(Rs. in Crores)

Sr No.	Particulars	For Quarter ended			Year ended
		June 30 , 2026	March 31 , 2026	June 30 , 2025	March 31 , 2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue From Operations	180.21	175.19	132.56	632.63
2	Other Income	2.81	17.67	8.79	47.06
3	**Total Income**	**183.02**	**192.86**	**141.35**	**679.69**
4	**Expenses**				
	Cost of materials consumed	31.15	27.05	29.38	114.27
	Purchases of stock-in-trade	34.01	35.71	27.55	137.32
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.56	3.46	4.43	0.07
	Employee benefits expenses	29.91	30.32	21.65	112.25
	Finance costs	7.17	8.46	5.04	25.03
	Depreciation & Amortisation expenses	9.94	9.30	5.99	31.25
	Other expenses	30.82	31.16	20.81	100.40
	Total expenses	**143.56**	**145.46**	**114.86**	**520.59**
5	**Profit before Tax**	**39.46**	**47.40**	**26.49**	**159.10**
6	**Tax expense**				
	Current tax	9.82	(4.97)	4.91	19.94
	Deferred tax	(0.81)	15.70	0.40	17.63
	Total Tax Expense	**9.01**	**10.73**	**5.31**	**37.57**
7	**Net Profit after tax**	**30.45**	**36.67**	**21.18**	**121.53**
8	**Other Comprehensive Income / (Loss)**				
	A (i) Items that will not be reclassified subsequently to profit or loss	0.00	0.24	-	(0.02)
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	(0.08)	-	(0.01)
	B (i) Items that will be reclassified subsequently to profit or loss	0.51	41.76	0.47	29.22
	(ii) Income tax relating to items that will be reclassified to profit and loss	-	-	-	-
	Total Other Comprehensive Income / (Loss)	**0.51**	**41.92**	**0.47**	**29.19**
9	**Total Comprehensive Income**	**30.96**	**78.59**	**21.65**	**150.72**
10	**Profit for the period attributable to**				
	Equity Holders of the Company	30.72	31.61	19.73	115.38
	Non Controlling Interests	(0.27)	5.06	1.45	6.16
	Other Comprehensive Income attributable to				
	Equity Holders of the Company	0.48	36.95	0.32	26.96
	Non Controlling Interests	0.03	4.97	0.15	2.23
	Total Comprehensive Income attributable to				
	Equity Holders of the Company	31.20	68.56	20.05	142.34
	Non Controlling Interests	(0.24)	10.03	1.60	8.39
11	**Paid up Equity Share Capital (Face Value Rs 10 per share)**				46.05
12	**Other Equity**				887.55
13	**Earnings per share (in Rupees) (Face Value Rs 10 per share)** ***(Not annualised for the quarter)***				
	Basic	6.61	7.96	4.60	26.39
	Diluted	6.60	7.96	4.60	26.39

Senores Pharmaceuticals Limited Ahmedabad

For Senores Pharmaceuticals Limited

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

Place : Ahmedabad
Date : July 27,2026

Notes to Consolidated Financial Results:

1. The unaudited consolidated financial results of Senores Pharmaceuticals Limited ("Company") for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meetings held on July 27, 2026. The Statutory auditors have carried out a limited review of the consolidated financial results of the Company for the quarter ended June 30, 2026.

2. The unaudited consolidated financial results of Senores Pharmaceuticals Limited have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

3. The figures for the last quarter ended March 31, 2026 are balancing figures between the audited figures in respect of the full year ending March 31, 2026 and the unaudited published year to date figures up to December 31, 2025, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

4. The unaudited consolidated financial results include the results of the following subsidiaries and step-down subsidiaries:

   i. Senores Pharmaceuticals Inc
   ii. Havix Group Inc
   iii. Ratnatris Pharmaceuticals Private Limited
   iv. Apnar Pharma Private Limited
   v. 9488 Jackson Trail LLC (Step-Down Subsidiary)
   vi. Zoraya Pharmaceuticals LLC (Step-Down Subsidiary)
   vii. Amerisyn, LLC (Step-Down Subsidiary)

5. Senores Pharmaceuticals Inc, wholly owned subsidiary of the Company, has entered into an Operating Agreement dated April 02, 2026 ("Agreement") to form a company named Amerisyn, LLC ("Amerisyn"). As per the terms of the Agreement SPI has subscribed to 70% of the membership interest in Amerisyn, which accordingly, has become a step-down subsidiary of the Company.

6. During the previous year, the Holding Company had acquired 75% equity stake in Apnar Pharma Private Limited ("Apnar") on 16th January, 2026 in accordance with the Share Purchase Agreement ("SPA") with its selling Shareholders. As per the SPA, the balance 25% equity stake in Apnar will be acquired post completion of due certain formalities as mentioned in the SPA. The consideration payable to the remaining selling shareholders is disclosed under the Financial Liabilities. The Company has made line by line consolidation of items of profit and loss and Balance sheet after Acquisition and has given effect of Goodwill arising out of this Acquisition as per IND AS 103 while preparing these consolidated unaudited financial results.

7. The Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.

Senores Pharmaceuticals Limited
Ahmedabad

8. The Proceeds of IPO have been utilized till June 30, 2026 as per the below mentioned table:

(Rs in crores)

Sr. No	Item Head	Amount as proposed in the Offer Document and as Revised as on June 30, 2026	Amount utilized till June 30, 2026	Amount unutilized as on June 30, 2026	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility *(Refer Note 1)*	107.00	6.98	100.02	Out of the unutilized amount, Rs 100.44 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.10 crores held in HDFC bank account.
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company *(Refer Note 3)*	73.10	73.10	0.00	
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00	
4	Funding the working capital requirements of our Company	43.26	43.26	0.00	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes *(Refer Notes 2 & 3)*	161.91	161.63	0.28	
7	Offer expenses *(Refer Note 3)*	35.04	34.80	0.24	
	Total	**500.00**	**399.46**	**100.54**	

Note 1: The company has sought shareholders' approval through postal ballot for variation in the objects / terms of utilisation of IPO proceeds and extension of time limit by curtailing the Object 1 to make investment in one of the subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in Atlanta Facility.

Note 2: During the quarter, Rs. 4.47 crores have been utilized towards General Corporate Purpose (GCP) for Object 6. Out of total utilized funds of Rs. 161.63 crores for Object 6, Rs. 69.80 crores is towards General Corporate Purpose (GCP) and Rs 91.83 is utilized towards other strategic initiatives till June 30, 2026.

Note 3:

i. Surplus portion of Rs. 0.38 crores on fulfillment of Object 2 & Rs. 0.02 crores on fulfillment of Object-3 are transferred to Object-6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated July 23, 2025.

ii. Surplus portion of Rs. 6.31 crores of Object 7 have been transferred to Object 6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated March 28, 2026.

iii. Out of the surplus portion of Offer expenses Rs.0.84 crore is transferred to the object of Funding inorganic growth through acquisition and other strategic initiatives and General Corporate Purpose (GCP) as approved in the board meeting dated May 14, 2026.

Senores Pharmaceuticals Limited Ahmedabad

9. The Board of Directors, at its meeting held on March 28, 2026, allotted 11,70,000 warrants to the Promoter and Promoter Group on a preferential basis, aggregating Rs 95 crore at an issue price of Rs 812 per warrant, pursuant to the shareholders' approval received on January 31, 2026. Each warrant is convertible into one equity share within 18 months from the date of allotment. During the year ended March 31, 2026, the Company received Rs 23.75 crore, representing the minimum upfront subscription amount of 25% of the issue price.

10. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.

11. The Group is operating in a single segment i.e. Pharmaceuticals. Hence, the above financial results are based on a single segment only.

12. Previous period figures have been regrouped and / or re-arranged wherever necessary to make their classification comparable with current period.

Senores Pharmaceuticals Limited Ahmedabad

For Senores Pharmaceuticals Limited

Place: Ahmedabad
Date: July 27, 2026

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

CA. DR. Pankaj Shah B.Com., F.C.A., Ph. D. (Commerce) | CA. Chintan Shah B.Com., L.L.B., F.C.A. | CA. Nilesh Shah B.Com., L.L.B., F.C.A. | CA. Manali Shah B.Com., F.C.A. | CA. Sandip Gupta B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. **URL : http://www.prsca.in**

Independent Auditors' Limited Review Report on Quarterly unaudited Standalone Ind AS Financial Results of M/s Senores Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,

The Board of Directors

Senores Pharmaceuticals Limited

Report on audit of Standalone Ind AS Financial Results

We have reviewed the accompanying Statement of Standalone Ind AS Financial Results of Senores Pharmaceuticals Limited (the "Company"), for the quarter ended June 30, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

Tax Provision and Deferred Tax has been determined as estimated by the management. Our conclusion on the statement is not modified in the respect of these matters.

For Pankaj R Shah & Associates
Chartered Accountants
(Firm Regn.No.107361W)

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

N. R. Shah

CA Nilesh Shah
Partner
Membership No. 107414
UDIN : 26107414MZQHHM5298
Place: Ahmedabad
Date: 27-07-2026

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | **Website:** www.senorespharma.com | **Phone:** +91-79-29999857 | **E-mail:** cs@senorespharma.com

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30,2026

(Rs. in Crores)

Sr No.	Particulars	For Quarter ended			Year ended
		June 30 , 2026	March 31 , 2026	June 30 , 2025	March 31 , 2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue From Operations	26.99	36.81	16.13	106.09
2	Other Income	9.55	22.19	12.08	66.35
3	**Total Income**	**36.54**	**59.00**	**28.21**	**172.44**
4	**Expenses**				
	Cost of materials consumed	7.47	18.36	1.40	24.55
	Purchases of stock-in-trade	4.19	5.10	2.34	30.42
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.49	0.06	3.41	(0.30)
	Employee benefits expenses	10.10	11.12	6.91	38.78
	Finance costs	2.22	1.89	1.76	6.98
	Depreciation & Amortisation expenses	3.61	4.13	1.88	13.23
	Other expenses	7.07	5.65	6.92	31.32
	Total expenses	**35.15**	**46.31**	**24.62**	**144.98**
5	**Profit before Tax**	**1.39**	**12.69**	**3.59**	**27.46**
6	**Tax expense**				
	Current tax	0.31	6.48	0.39	8.45
	Deferred tax	0.05	(2.27)	0.51	(1.24)
	Total Tax Expense	**0.36**	**4.21**	**0.90**	**7.21**
7	**Net Profit after tax**	**1.03**	**8.48**	**2.70**	**20.25**
8	**Other Comprehensive Income / (Loss)**				
	A (i) Items that will be reclassified to profit or loss	0.00	0.09	-	(0.01)
	(ii) Income tax relating to items that will be reclassified to profit and loss	(0.00)	(0.03)	-	0.00
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	-	-	-
	Total Other Comprehensive Income / (Loss)	**0.00**	**0.06**	**-**	**(0.01)**
9	**Total Comprehensive Income**	**1.03**	**8.54**	**2.70**	**20.24**
10	**Paid up Equity Share Capital (Face Value Rs 10 per share)**				46.05
11	**Other Equity**				703.85
12	**Earnings per share (in Rupees) (Face Value Rs 10 per share)** ***(Not annualised for the quarter)***				
	Basic	0.22	1.84	0.59	4.40
	Diluted	0.22	1.84	0.59	4.40

For Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited Ahmedabad

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

Place : Ahmedabad
Date : July 27,2026

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Notes to Standalone Financial Results:

1. The standalone unaudited financial results of Senores Pharmaceuticals Limited ("Company") for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meetings held on July 27, 2026. The Statutory auditors have carried out a limited review of the standalone financial results of the Company for the quarter ended June 30, 2026.

2. The standalone unaudited financial results of Senores Pharmaceuticals Limited have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

3. The figures for the last quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full year ending March 31, 2026 and the unaudited published year-to-date figures up to December 31, 2025, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

4. The Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.

5. The Proceeds of IPO have been utilized till June 30, 2026 as per the below mentioned table:

Sr. No	Item Head	Amount as proposed in the Offer Document and as Revised as on June 30, 2026	Amount utilized till June 30, 2026	Amount unutilized as on June 30, 2026	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility (Refer Note 1)	107.00	6.98	100.02	Out of the unutilized amount, Rs 100.44 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.10 crores held in HDFC bank account.
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company *(Refer Note 3)*	73.10	73.10	0.00	
3	Investment in our Subsidiary, namely, Havix, for re-payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00	
4	Funding the working capital requirements of our Company	43.26	43.26	0.00	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes *(Refer Notes 2 & 3)*	161.91	161.63	0.28	
7	Offer expenses *(Refer Note 3)*	35.04	34.80	0.24	
	Total	**500.00**	**399.46**	**100.54**	

Senores Pharmaceuticals Limited Ahmedabad

Note 1: The company has sought shareholders' approval through postal ballot for variation in the objects / terms of utilisation of IPO proceeds and extension of time limit by curtailing Object 1 to make investment in one of the subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in Atlanta Facility.

Note 2: During the quarter, Rs. 4.47 crores have been utilized towards General Corporate Purpose (GCP) for Object 6. Out of total utilized funds of Rs. 161.63 crores for Object 6, Rs. 69.80 crores is towards General Corporate Purpose (GCP) and Rs 91.83 is utilized towards other strategic initiatives till June 30, 2026.

Note 3:

i. Surplus portion of Rs. 0.38 crores on fulfillment of Object-2 & Rs. 0.02 crores on fulfillment of Object-3 are transferred to Object-6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated July 23, 2025.

ii. Surplus portion of Rs. 6.31 crores of Object 7 have been transferred to Object 6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated March 28, 2026.

iii. Out of the surplus portion of Offer Expenses Rs.0.84 crore is transferred to the object of Funding inorganic growth through acquisition and other strategic initiatives and General Corporate Purpose (GCP) as approved in the board meeting dated May 14,2026.

7. The Board of Directors, at its meeting held on March 28, 2026, allotted 11,70,000 warrants to the Promoter and Promoter Group on a preferential basis, aggregating ₹95 crore at an issue price of ₹812 per warrant, pursuant to the shareholders' approval received on January 31, 2026. Each warrant is convertible into one equity share within 18 months from the date of allotment. During the year ended March 31, 2026, the Company received ₹23.75 crore, representing the minimum upfront subscription amount of 25% of the issue price.

8. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.

9. The Company operates in a single segment i.e. Pharmaceuticals. Hence, the above financial results are based on a single segment only.

10. Previous period figures have been regrouped and/or rearranged, wherever necessary to make their classification comparable with current period.

For Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited Ahmedabad

Place: Ahmedabad
Date: July 27, 2026

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821